
“CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Surpasses Revenue Expectations: A Closer Look at the Tale of the Tape”
CRISPR Therapeutics AG Quarterly Loss Analysis Understanding the Quarterly Loss CRISPR Therapeutics AG (CRSP) recently reported a quarterly loss of $0.44 per share, which was significantly better than the Zacks Consensus Estimate of a loss of $1.15. This is a substantial improvement compared to earnings of $1.10 per share from the same quarter a year…